At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
Ibrutinibdrug
Likely dose
Ibrutinib 420mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Inhibition of Anaphylaxis by Ibrutinib
Ann & Robert H Lurie Children's Hospital of Chicago·interventional·Posted May 11, 2017·Updated Jan 17, 2025
In Brief
A Phase 2 clinical trial evaluating Ibrutinib for Food Allergy and Anaphylaxis Food. Completed, enrolled 6 participants across 1 site.
Detailed Summary
This is a phase II open label study on the use of Ibrutinib on the inhibition of food-induced anaphylaxis in adults with food allergy. Ibrutinib (brand name Imbruvica) is currently FDA approved for the treatment of mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenstrom's macroglobulineia (WM). We propose to administer this approved drug to adults with food allergy to inhibit food allergy responses.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFood Allergy, Anaphylaxis Food
CountriesUnited States
CollaboratorsNorthwestern University
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartApr 2017
First PostedMay 2017
Primary CompletionNov 2018
TodayJul 2026
First PostedMay 11, 2017
Enrollment StartApr 10, 2017
Primary CompletionNov 14, 2018
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 9.1 years ago
Interventions
Ibrutinibdrug
Ibrutinib 420mg, PO once daily for 2-7 days